MRNA Moderna
Market prices an oncology blockbuster story the current numbers can't yet support; priced well above intrinsic value.
The story
Moderna is an mRNA platform company whose COVID windfall has collapsed. Revenue has fallen from 18.9B to about 2.2B, and the company is losing over 3B a year. A market cap near 90B prices in a second act: oncology (the individualized neoantigen therapy with Merck), respiratory combination vaccines and rare-disease programs that turn into multiple blockbusters. Its moat is manufacturing scale, speed and IP in mRNA, but competition and pricing pressure are eroding the platform's edge. That makes this a restart-stage biotech, not a mature franchise.
I am stretching toward the market's view. I use a 12-year horizon and fast launch-driven growth fading to 3%, which takes revenue to roughly 25-30B, plus a 33% margin in line with large-cap pharma. Sales-to-capital of 1.5 assumes reinvestment efficiency normalizes from today's depressed 0.24 once R&D spending is matched by product revenue. Beta of 1.25 and an 8% failure probability reflect cash burn of over 3B a year against 2.6B of cash. Even with these generous drivers, value comes out around 55-70 USD a share. Only a 40B+ oncology-led revenue path would justify the price, and I treat that as an upside scenario, not the base case.
Value drivers
| Revenue growth (Y1) | 45.0% |
| Terminal growth | 3.0% |
| Forecast horizon | 12y |
| Target operating margin | 33.0% |
| Years to target margin | 8 |
| Sales-to-capital | 1.50 |
| Beta | 1.25 |
| Failure probability | 8.0% |
| Cost of capital (WACC) | 10.7% |
| Terminal WACC | 9.6% |
Valuation bridge
| PV of explicit FCFF | -9.31B |
| PV of terminal value | 22.44B |
| Equity value | 13.93B |
| ÷ shares → per share | $34.89 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 3.20B | 45.0% | -116.4% | -2.95B | 663.00M | -3.61B | -3.26B |
| 2 | 4.52B | 41.2% | -95.1% | -3.40B | 879.78M | -4.28B | -3.49B |
| 3 | 6.21B | 37.4% | -73.7% | -3.62B | 1.13B | -4.75B | -3.50B |
| 4 | 8.30B | 33.5% | -52.4% | -3.44B | 1.39B | -4.82B | -3.21B |
| 5 | 10.77B | 29.7% | -31.0% | -2.64B | 1.64B | -4.29B | -2.57B |
| 6 | 13.56B | 25.9% | -9.7% | -1.04B | 1.86B | -2.90B | -1.57B |
| 7 | 16.55B | 22.1% | 11.7% | 1.52B | 2.00B | -472.91M | -231.76M |
| 8 | 19.57B | 18.3% | 33.0% | 5.10B | 2.02B | 3.09B | 1.37B |
| 9 | 22.40B | 14.5% | 33.0% | 5.84B | 1.89B | 3.95B | 1.58B |
| 10 | 24.79B | 10.6% | 33.0% | 6.46B | 1.59B | 4.87B | 1.76B |
| 11 | 26.48B | 6.8% | 33.0% | 6.90B | 1.13B | 5.78B | 1.88B |
| 12 | 27.27B | 3.0% | 33.0% | 7.11B | 529.54M | 6.58B | 1.94B |
Key risks
- Oncology Phase 3 or label disappointments for the neoantigen therapy, which would remove the main pillar of the valuation
- Cash burn forcing dilutive equity raises before product revenue arrives
- Respiratory vaccine pricing pressure, falling vaccination uptake and US policy hostility toward mRNA
Catalysts
- Approvals and launch uptake of the melanoma neoantigen therapy and readouts in other tumor types
- Cost cuts bringing operating breakeven forward and sales of respiratory combination vaccines
⚠ Extreme gap to market price — large, heavily-covered stocks are rarely mispriced this much; the gap likely embeds disruption, decline, or balance-sheet risk the model underweights. Treat as a flag to investigate, not a verdict.